Gluskin Sheff & Assoc Has Increased By $2.39 Million Its Novartis Ag (NVS) Holding; Anheuser Busch Inbev NV (ADR) (BUD) Covered By 14 Bulls

September 17, 2017 - By Nellie Frank

Among 22 analysts covering Anheuser-Busch InBev (NYSE:BUD), 14 have Buy rating, 1 Sell and 7 Hold. Therefore 64% are positive. Anheuser-Busch InBev had 40 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was downgraded by Societe Generale on Tuesday, April 5 to “Buy”. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, August 30. The firm earned “Buy” rating on Tuesday, December 8 by HSBC. The firm earned “Buy” rating on Monday, October 3 by Liberum Capital. The rating was maintained by Susquehanna on Friday, May 5 with “Hold”. The stock has “Buy” rating by Jefferies on Tuesday, September 13. The company was downgraded on Thursday, October 20 by Societe Generale. The firm has “Hold” rating given on Wednesday, August 26 by ING Group. The firm has “Outperform” rating by BNP Paribas given on Monday, November 16. The firm earned “Overweight” rating on Wednesday, October 5 by Morgan Stanley. See Anheuser Busch Inbev NV (ADR) (NYSE:BUD) latest ratings:

13/09/2017 Broker: Berenberg Rating: Buy
08/09/2017 Broker: Argus Research Rating: Buy New Target: $136.00 Initiate
30/08/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $140.0 Maintain
28/07/2017 Broker: Jefferies Rating: Buy New Target: $139.0000 Maintain
27/07/2017 Broker: Susquehanna Rating: Hold New Target: $111.0000 Maintain
10/07/2017 Broker: Goldman Sachs Rating: Buy Maintain
27/06/2017 Broker: Jefferies Rating: Buy New Target: $132.0000 Maintain
23/06/2017 Broker: Stifel Nicolaus Rating: Buy Old Target: $134.00 New Target: $140.00 Target Up
05/05/2017 Broker: Susquehanna Rating: Hold New Target: $103.00 Maintain

Gluskin Sheff & Assoc Inc increased Novartis Ag (NVS) stake by 30.78% reported in 2016Q4 SEC filing. Gluskin Sheff & Assoc Inc acquired 33,200 shares as Novartis Ag (NVS)’s stock rose 4.17%. The Gluskin Sheff & Assoc Inc holds 141,070 shares with $10.28M value, up from 107,870 last quarter. Novartis Ag now has $223.91B valuation. The stock decreased 0.29% or $0.25 on September 15, reaching $85.58. About 1.93M shares traded or 21.38% up from the average. Novartis AG (ADR) (NYSE:NVS) has risen 7.67% since September 17, 2016 and is uptrending. It has underperformed by 9.03% the S&P500.

Among 15 analysts covering Novartis Ag (NYSE:NVS), 5 have Buy rating, 2 Sell and 8 Hold. Therefore 33% are positive. Novartis Ag had 30 analyst reports since July 28, 2015 according to SRatingsIntel. On Monday, October 10 the stock rating was maintained by Chardan Capital Markets with “Buy”. The company was downgraded on Tuesday, March 29 by Citigroup. JP Morgan maintained the shares of NVS in report on Wednesday, April 19 with “Neutral” rating. Goldman Sachs maintained the shares of NVS in report on Thursday, March 23 with “Neutral” rating. The firm earned “Hold” rating on Tuesday, April 5 by Argus Research. Argus Research upgraded Novartis AG (ADR) (NYSE:NVS) on Thursday, November 10 to “Buy” rating. As per Monday, September 11, the company rating was maintained by Cowen & Co. The firm has “Hold” rating given on Tuesday, July 18 by Cowen & Co. J P Morgan Chase Co maintained the shares of NVS in report on Friday, June 16 with “Neutral” rating. Chardan Capital Markets initiated Novartis AG (ADR) (NYSE:NVS) rating on Tuesday, September 20. Chardan Capital Markets has “Buy” rating and $95.0 target.

Gluskin Sheff & Assoc Inc decreased Oracle Corporation (NYSE:ORCL) stake by 11,820 shares to 662,468 valued at $25.47M in 2016Q4. It also reduced Allergan Plc stake by 1,795 shares and now owns 102,916 shares. Broadcom Ltd was reduced too.

The stock decreased 0.72% or $0.88 on September 15, reaching $120.86. About 1.01 million shares traded. Anheuser Busch Inbev NV (ADR) (NYSE:BUD) has declined 3.55% since September 17, 2016 and is downtrending. It has underperformed by 20.25% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com